Search results

Technologies 2

• MRBL: Next-Generation Gene Therapy for Molecular Skin Rejuvenation
  The next-generation gene therapy for molecular skin rejuvenation combines a comprehensive target gene prediction with a novel transdermal delivery approach for therapeutic adenovirus-associated viruses. The platform targets monogenic disease indications in the skin, and extends the same targets to the treatment of common skin aging conditions.
• Synthetic AAV Capsids for Advanced Gene Therapy
  The protein shell (capsid) of Adeno-associated viruses (AAV) are presently the most promising delivery vehicles for various in vivo gene therapies. AAVs are non-pathogenic and, through past engineering efforts, have become safe due to their inability to integrate into and damage the genome of target cells. Rather, the delivered DNA containing a therapeutic gene of...

News 10

View all

• Press Release
  
  Machine-learning how to create better AAV gene delivery vehicles
  February 11, 2021
• Press Release
  
  A new vision for AAV-delivered gene therapies
  February 10, 2021
• Translation News
  
  Rejuvenate Bio launches to help dogs live longer, healthier lives
  February 6, 2020

Multimedia 2

• 

  Video/Animation
  Improving Canine Healthspan
  A Wyss Institute technology that can treat multiple age-related diseases is now being developed by Rejuvenate Bio into a treatment for mitral valve disease and other deadly conditions in dogs, with the goal of helping man’s best friend live longer, healthier lives. Credit: Wyss Institute at Harvard University

• 

  Video/Animation
  AAV Capsid Engineering
  Wyss researchers have created a high-throughput platform to generate an Adeno-associated virus 2 (AAV2) library containing 200,000 variants, each carrying a distinct mutation in the virus capsid protein. Their analysis identified capsid changes that enhanced “homing” potential to specific organs in mice and virus viability, as well as a new protein hidden in the capsid-encoding...